Alnylam Pharmaceuticals Inc. (ALNY) and Sanofi Genzyme announced Wednesday morning that their Phase 3 study of patisiran, in patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary endpoint and all secondary endpoints.
from RTT - Before the Bell http://ift.tt/2xxp2yU
via IFTTT
No comments:
Post a Comment